Filing Flows › Emergent BioSolutions (EBS) › Recalls, complaints & regulation
Emergent BioSolutions (EBS): clinical trials
Emergent BioSolutions (EBS) beyond its filings: 7 active clinical trials.
Emergent BioSolutions' latest quarter
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Emergent BioSolutions have?
7 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.